Skip to main content
Vericel Corp logo

Vericel Corp — Investor Relations & Filings

Ticker · VCEL ISIN · US92346J1088 LEI · 54930076YM3PLTDR4B91 US Manufacturing
Open in API
Filings indexed 1,130 across all filing types
Latest filing 2010-08-27 Director's Dealing
Country US United States of America
Listing US VCEL

About Vericel Corp

https://vcel.com/

Vericel Corporation is a biopharmaceutical company that develops, manufactures, and commercializes advanced cell therapies for the sports medicine and severe burn care markets. The company's portfolio is centered on autologous (patient-specific) cell-based products. Key commercial products include MACI® (autologous cultured chondrocytes on porcine collagen membrane), a tissue-engineered product for the repair of symptomatic cartilage defects of the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for patients with severe burns. Additionally, Vericel holds the exclusive North American commercial rights for NexoBrid®, a biological orphan product used for the removal of eschar in adults with deep partial-thickness or full-thickness thermal burns.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2010-08-27 English
4 Filing
Director's Dealing
2010-08-27 English
4 Filing
Director's Dealing
2010-08-27 English
3 Filing
Director's Dealing
2010-08-27 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 17, 2010, reporting the results of operations and financial condition for the fourth quarter ended June 30, 2010. It references a press release announcing operating results, attached as Exhibit 99.1. The text explicitly states that the report and exhibit are not deemed to be filed for purposes of Section 18 and are not incorporated by reference into other filings. The document is short (2552 characters) and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or substantive financial data itself. According to the rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). This document fits the description of an Earnings Release announcement rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2010-08-17 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically announces the date of the 2010 Annual Meeting of Shareholders and related shareholder proposal deadlines. It includes a press release as Exhibit 99.1. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is primarily an announcement of an event related to the annual meeting, not the meeting materials themselves or voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2010-08-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.